United Kingdom (UK)
Recombinant monoclonal antibody to Beta Lactamase. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the camel peripheral lymphocytes cAbTEM13.
UniProt Accession Number of Target Protein: P62593
Alternative Name(s) of Target: β-Lactamase; bla; Beta-lactamase TEM; IRT-4; Penicillinase; TEM-1 β-lactamase; cAb-TEM13
Immunogen: The original antibody was generated by immunizing adult dromedary (Camelus dromedarius) with TEM-1 β-lactamase.
Specificity: This antibody binds an enzyme called beta-lactamase produced by bacteria, which catalysis the breaking of the beta-lactam ring of beta-lactam antibiotics such as penicillin, cephalosporin, cephamycin and monobactam through hydrolysis. The breaking of the beta-lactam ring deactivates the antibacterial properties of the antibiotic molecule and provides antibiotic resistance in bacteria.
Application Notes: The binding reactivity of this antibody to TEM-1 beta-lactamase was determined using ELISA. This antibody was capable of inhibiting beta-lactamase activity in vitro with an IC50 of 0.08 μM. The in vivo inhibition activity of this antibody to inhibit surface-exposed TEM-1 and prevent bacterial growth was assessed by preincubating cells expressing TEM-1 with increasing amounts of the antibody fragment. It was reported that when cells were preincubated with cAbTem13 before plating lost their ability to neutralize the antibiotic ampicillin (PMID: 11557473).
Antibody first published in:
Conrath et al. β-Lactamase inhibitors derived from single-domain antibody fragments elicited in the Camelidae. Antimicrob Agents Chemother. 2001 Oct; 45(10): 2807–2812. PMID:11557473
Note on publication:
Describes the generation of B-lactamase inhibitory antibodies derived from camels.